Mylan And Upjohn Put A Price On $11.5bn Viatris Debt
Delayed Combination Of The Two Firms Is Set For Q4
Upjohn is to pay parent company Pfizer $12bn in cash in order to complete its separation and merger with Mylan to form Viatris, a new company set to be unveiled by the end of this year following a delay caused by the COVID-19 pandemic. Details of the debt financing tapped into the by the company have just been announced.
